Catalyst

Slingshot members are tracking this event:

REVOLUTION Medicines'(RVMD) SHP2 (RMC-4630) to Report Phase 1 monotherapy dose escalation safety data in cancer, in 1H 2021

Source Link:
http://www.globenewswire.com/news-release/2020/11/12/2125489/0/en/Revolution-Medicines-Reports-Third-Quarter-2020-Financial-Results-and-Update-on-Corporate-Progress.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RVMD Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Future Window:
Jan 01, 2021 - Jun 30, 2021
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Shp2, Rmc-4630
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.